Moxifcin

Resp tract infection; acute bacterial sinusitis caused by Strep pneumoniae, H. influenzae or Moraxella catarrhalis; acute bacterial exacerbation of chronic bronchitis caused by Strep pneumoniae, H. influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staph aureus or Moraxella catarrhalis; mild to moderate community-acquired pneumoniae caused by Strep pneumoniae, H. influenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae or Moraxella catarrhalis. Uncomplicated skin & skin structure infections caused by Staph aureus or Strep pyogenes. Complicated skin & skin structure infections caused by methicillin-susceptible Staph aureus, E. coli, Klebsiella pneumoniae or Enterobacteriaceae. Mild to moderate pelvic inflammatory disease w/o associated tubo-ovarian or pelvic abscess; should be given in combination w/ another appropriate antibacterial agent (eg, cephalosporin) due to increasing moxifloxacin resistance of Neisseria gonorrhoeae.

Adult 400 mg once daily. Acute exacerbation of chronic bronchitis Duration of treatment: 5 days. Acute sinusitis Duration of treatment: 7 days. Uncomplicated skin & skin structure infection Duration of treatment: 7 days. Mild to moderate community-acquired pneumonia Duration of treatment: 10 days. Total duration for sequential administration (IV followed by oral therapy): 7-14 days. Complicated skin & skin structure infection Total treatment duration for sequential therapy (IV followed by oral therapy): 7-21 days. Mild to moderate pelvic inflammatory disease Duration of treatment: 14 days.

May be taken with or without food: Swallow whole w/ sufficient liqd/water.

Hypersensitivity to moxifloxacin or other quinolones. Patients w/ history of tendon disease/disorder related to quinolone treatment. Patients w/ congenital or documented acquired QT prolongation; electrolyte disturbances particularly in uncorrected hypokalaemia; clinically relevant bradycardia or heart failure with reduced left-ventricular ejection fraction; history of symptomatic arrhythmias. Do not use concurrently w/ other QT interval-prolonging drugs. Patients w/ increased transaminases >5-fold ULN. Impaired liver function (Child-Pugh C). Pregnancy & lactation. Patients <18 yr.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

POM